Biodistribution, plasma kinetics and quantification of single-pass pulmonary clearance of adrenomedullin

被引:34
作者
Dupuis, J
Caron, A
Ruël, N
机构
[1] Montreal Heart Inst, Res Ctr, Montreal, PQ H1Y 1C8, Canada
[2] Univ Montreal, Montreal, PQ H1Y 1C8, Canada
关键词
adrenomedullin; pharmacokinetics; peptide hormone; pulmonary circulation; vasoactive agent;
D O I
10.1042/CS20040357
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The biodistribution, pharmacokinetics and multi-organ clearance of the vasodilator peptide AM (adrenomedullin) were evaluated in rats and its single-pass pulmonary clearance was measured in dogs by the indicator-dilution technique. Intravenously administered I-125-rAM(1-50) [rat AM(1-50)] was rapidly cleared following a two-compartment model with a very rapid distribution half-life of 2.0 min [95 % CI (confidence interval), 1.98-2.01] and an elimination half-life of 15.9 min (95 % CI, 15.0-16.9). The lungs retained most of the injected activity with evidence of single-pass clearance, since retention was lower after intra-arterial (13.5 +/- 0.6 %) compared with intravenous (30.4 +/- 1.5 %; P < 0.001) injection. Lung tissue levels of total endogenous AM were 20-fold higher than in other organs with no difference in plasma levels across the pulmonary circulation. In dogs, there was 36.4 +/- 2.1 % first-pass unidirectional extraction of I-125-rAM(1-50) by the lungs that was reduced to 21.9 +/- 2.4 % after the administration of unlabelled rAM(1-50) (P < 0.01). Extraction was not affected by calcitonin-gene-related peptide administration (40.6 +/- 2.9 %), but was slightly reduced by the C-terminal fragment of human AM(22-52) (31.4 +/- 3.3 %; P < 0.01). These data demonstrate that. the lungs are a primary site for AM clearance in vivo with approx. 36 % first-pass extraction through specific receptors. This suggests that the lungs not only modulate circulating levels of this peptide, but also represent its primary target.
引用
收藏
页码:97 / 102
页数:6
相关论文
共 22 条
[11]   The seven amino acids of human RAMP2 (86-92) and RAMP3 (59-65) are critical for agonist binding to human adrenomedullin receptors [J].
Kuwasako, K ;
Kitamura, K ;
Ito, K ;
Uemura, T ;
Yanagita, Y ;
Kato, J ;
Sakata, T ;
Eto, T .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (52) :49459-49465
[12]   Adrenomedullin receptor expression in human lung and in pulmonary tumors [J].
Martinez, A ;
Miller, MJ ;
Catt, KJ ;
Cuttitta, F .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1997, 45 (02) :159-164
[13]   Rat receptor-activity-modifying proteins (RAMPs) for adrenomedullin/CGRP receptor: Cloning and upregulation in obstructive nephropathy [J].
Nagae, T ;
Mukoyama, M ;
Sugawara, A ;
Mori, K ;
Yahata, K ;
Kasahara, M ;
Suganami, T ;
Makino, H ;
Fujinaga, Y ;
Yoshioka, T ;
Tanaka, I ;
Nakao, K .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 270 (01) :89-93
[14]   Production and clearance sites of two molecular forms of adrenomedullin in human plasma [J].
Nishikimi, T ;
Matsuoka, H ;
Shimada, K ;
Matsuo, H ;
Kangawa, K .
AMERICAN JOURNAL OF HYPERTENSION, 2000, 13 (09) :1032-1034
[15]   The active molecular form of plasma adrenomedullin is extracted in the pulmonary circulation in patients with mitral stenosis: possible role of adrenomedullin in pulmonary hypertension [J].
Nishikimi, T ;
Nagata, S ;
Sasaki, T ;
Yoshihara, F ;
Nagaya, N ;
Horio, T ;
Matsuo, H ;
Matsuoka, H ;
Kangawa, K .
CLINICAL SCIENCE, 2001, 100 (01) :61-66
[16]   CLINICAL-STUDIES ON THE SITES OF PRODUCTION AND CLEARANCE OF CIRCULATING ADRENOMEDULLIN IN HUMAN-SUBJECTS [J].
NISHIKIMI, T ;
KITAMURA, K ;
SAITO, Y ;
SHIMADA, K ;
ISHIMITSU, T ;
TAKAMIYA, M ;
KANGAWA, K ;
MATSUO, H ;
ETO, T ;
OMAE, T ;
MATSUOKA, H .
HYPERTENSION, 1994, 24 (05) :600-604
[17]   AN ABUNDANT AND SPECIFIC BINDING-SITE FOR THE NOVEL VASODILATOR ADRENOMEDULLIN IN THE RAT [J].
OWJI, AA ;
SMITH, DM ;
COPPOCK, HA ;
MORGAN, DGA ;
BHOGAL, R ;
GHATEI, MA ;
BLOOM, SR .
ENDOCRINOLOGY, 1995, 136 (05) :2127-2134
[18]   International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors [J].
Poyner, DR ;
Sexton, PM ;
Marshall, I ;
Smith, DM ;
Quirion, R ;
Born, W ;
Muff, R ;
Fischer, JA ;
Foord, SM .
PHARMACOLOGICAL REVIEWS, 2002, 54 (02) :233-246
[20]   mRNA expression of novel CGRP1 receptors and their activity-modifying proteins in hypoxic rat lung [J].
Qing, X ;
Svaren, J ;
Keith, IM .
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2001, 280 (03) :L547-L554